HEMA - HemaCare Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
12.65
+0.10 (+0.80%)
At close: 2:54PM EDT
Stock chart is not supported by your current browser
Previous Close12.55
Open12.65
Bid0.16 x 5000
Ask10.00 x 500
Day's Range12.65 - 12.65
52 Week Range7.60 - 16.00
Volume2,935
Avg. Volume11,046
Market Cap140.463M
Beta (3Y Monthly)1.43
PE Ratio (TTM)36.04
EPS (TTM)0.35
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • Business Wire4 months ago

    HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State Samples

    HemaCare Corporation (HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, and Tissue Solutions Ltd, a leading global provider of diseased human biosamples for research, today announced their partnership to supply customers with an expanded selection of well-qualified disease-state biomaterials in fresh, frozen, and FFPE formats. Partnering with Tissue Solutions will allow HemaCare to further meet growing market needs by expanding its current disease-state product portfolio. HemaCare customers will now have access to pathology-verified frozen and FFPE tissues, as well as hard-to-source disease samples such as tumor tissues and dissociated tumor cells isolated from freshly resected tumors.

  • Business Wire4 months ago

    HemaCare Reports Full Year 2018 Results

    HemaCare Corporation , a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, today announced operational highlights and financial results for the year ended December 31, 2018.

  • ACCESSWIRE6 months ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • Business Wire6 months ago

    HemaCare to Chair and Present at Phacilitate Leaders World Supply Chain Panel Discussion

    HemaCare Corporation (HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, announced today that Dominic Clarke, Ph.D., Global Head of Cell Therapy, will chair and present at Phacilitate Leaders World, one of the largest Cell and Gene Therapy conferences globally.

  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zacks7 months ago

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • HemaCare Relocates Global Headquarters
    Business Wire8 months ago

    HemaCare Relocates Global Headquarters

    HemaCare Corporation (HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, today announced the company has moved its global headquarters to Northridge, California. The cell therapy industry continues to see a rapid increase in demand for high-quality starting material. HemaCare has become the number one most trusted supplier of human biological material for cell therapy customers around the world.

  • Business Wire8 months ago

    HemaCare Provides Starting Material for Three FDA Approved Cellular Therapies

    During the development process, HemaCare worked collaboratively with each company to source healthy donors per project requirements. In some cases, HemaCare performed further processing by splitting collections for comparability runs, freezing material, or adding isolated cells to mimic patient collection material.

  • Business Wire11 months ago

    HemaCare Details Expanded GMP Capabilities at CAR-TCR Summit in Boston, MA.

    HemaCare Corporation (HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces details of their expanded GMP capabilities at the annual CAR-TCR Summit on September 4-7, 2018. HemaCare will be relocating its operations and corporate headquarters to a larger, state-of-the-art facility with four GMP cleanrooms for expansion of GMP-compliant cells, tissues, and services.

  • Business Wire11 months ago

    HemaCare Reports First Half 2018 Results

    HemaCare Corporation , a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy, today announced operational highlights and financial results for the six months ended June 30, 2018.